Drug Profile
Research programme: CC-chemokine receptor 3 antagonists - Merck
Alternative Names: CCR3 chemokine receptor antagonists research programme - Merck & CoLatest Information Update: 29 Aug 2011
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Small molecules
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Allergic rhinitis; Asthma
Most Recent Events
- 29 Aug 2011 Discontinued - Preclinical for Allergic rhinitis in USA (unspecified route)
- 29 Aug 2011 Discontinued - Preclinical for Asthma in USA (unspecified route)
- 12 Jan 2006 No development reported for asthma and allergic rhinitis